

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board wishes to inform the Shareholders and potential investors that, based on a preliminary review of the Company's unaudited consolidated management accounts for the year ended 31 December 2018, the profit attributable to equity holders of the Company for the year ended 31 December 2018 is expected to record a significant increase ranging from 33% to 40% as compared with that of the year ended 31 December 2017.

The information contained in this announcement is only based on a preliminary review of the Company's unaudited consolidated management accounts for the year ended 31 December 2018. Such management accounts have not been audited by the Company's auditor or reviewed by the audit committee of the Company.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by SSY Group Limited (the "Company", together with its subsidiaries, collectively the "Group") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO").

The board of directors (the “Board”) of the Company wishes to inform the shareholders of the Company (the “Shareholders”) and potential investors that, based on a preliminary review of the Company’s unaudited consolidated management accounts for the year ended 31 December 2018, the profit attributable to equity holders of the Company for the year ended 31 December 2018 is expected to record a significant increase ranging from 33% to 40% as compared with that of the year ended 31 December 2017. Such expected increase was mainly due to, among other things, (i) increases in sales volume and average selling price of intravenous infusion solutions and (ii) increase in overall gross profit margin of the Group’s products due to a better product mix from products with higher profit margins and the Group’s continuous cost control measures.

The information contained in this announcement is only based on a preliminary review of the Company’s unaudited consolidated management accounts for the year ended 31 December 2018 and the information currently available to the Board. It is not based on any figures or information that have been audited by the Company’s auditor, or reviewed by the audit committee of the Company. The Company is still in the process of finalising the consolidated annual results of the Group for the year ended 31 December 2018. The finalised consolidated annual results and other details of the Group for the year ended 31 December 2018 will be published by the Company within the timeframe as stipulated under the Listing Rules.

Shareholders and potential investors are advised to read this announcement carefully and exercise caution when dealing in the shares of the Company.

By Order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 18 February 2019

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.